The Supreme Court on Tuesday dealt a fatal blow to an expansive Maryland law that aimed to bar drug makers from “price gouging” consumers. The law, which the Maryland General Assembly passed in 2017, would have prohibited generic drug manufacturers from raising prices in a manner the state deemed “unconscionable.”